Syndax Pharmaceuticals (SNDX) Change in Account Payables (2015 - 2026)

Syndax Pharmaceuticals' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$5.7 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 263.33% year-over-year to -$5.7 million in Q1 2026; TTM through Mar 2026 was $796000.0, a 35.7% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, up 197.54% from the prior year.
• Change in Account Payables declined to -$5.7 million in Q1 2026 per SNDX's latest filing, from $2.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $7.3 million in Q2 2025 and bottomed at -$6.7 million in Q3 2024.
• The 5-year median for Change in Account Payables is $676000.0 (2022), against an average of $304352.9.
• Biggest YoY gain for Change in Account Payables was 262.97% in 2023; the steepest drop was 829.29% in 2023.
• Year by year, Change in Account Payables stood at -$2.8 million in 2022, then surged by 241.53% to $3.9 million in 2023, then soared by 71.98% to $6.7 million in 2024, then plunged by 59.07% to $2.8 million in 2025, then tumbled by 308.32% to -$5.7 million in 2026.
• Per Business Quant, the three latest SNDX Change in Account Payables figures stand at -$5.7 million (Q1 2026), $2.8 million (Q4 2025), and -$3.5 million (Q3 2025).